Low-Androgen Tumors Respond To Anti-Androgen Therapy In Triple-Negative Breast Cancer

Low-Androgen Tumors Respond To Anti-Androgen Therapy In Triple-Negative Breast Cancer
shutterstock_189707846 - CópiaA study from the University of Colorado Cancer Center was recently published in the Molecular Cancer Therapeutics journal showing that only 1 percent of triple-negative breast cancer (TNBC) cells in a tumor have to be “androgen-receptor-positive” for the patient to benefit from anti-androgen based therapies. Currently, there are no FDA-approved targeted therapies to address TNBC. However, clinical trials are underway and reveal promising preliminary results to fight this type of cancer with anti-androgen-receptor based therapies that express a higher amount of androgen-receptor-positive cells. “What we’re showing is that the threshold for benefit from anti-androgen-receptor therapies in triple-negative breast cancer may be far lower than we previously thought. This is an extremely optimistic finding for many people who have been without options for targeted cancer therapy,” said Valerie Bart
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.